This database contains 175 studies, archived under the term: "administration & dosage"
Click here to filter this large number of results.
Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease
Gehrman, Philip R.,
Connor, Donald J.,
Martin, Jennifer L.,
Shochat, Tamar,
Corey-Bloom, Jody,
Ancoli-Israel, Sonia
Objectives: Patients with Alzheimer dementia often display both agitated behavior and poor sleep. Given that the disease is often associated with low endogenous levels of melatonin, exogenous melatonin administration may lead to improvements in sleep and agitation.; Design: Randomized, placebo-controlled study.; Setting: Nursing homes in San Diego, CA, metropolitan area.; Participants: Subjects were patients with […]
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial
Doody, R. S.,
Ferris, S. H.,
Salloway, S.,
Sun, Y.,
Goldman, R.,
Watkins, W. E.,
Xu, Y.,
Murthy, A. K.
Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.; Methods: In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included change […]
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex
Marras, Connie,
Herrmann, Nathan,
Anderson, Geoffrey M.,
Fischer, Hadas D.,
Wang, Xuesong,
Rochon, Paula A.
Background: Differences between atypical antipsychotics in their potential to cause parkinsonism and risk factors for antipsychotic-induced parkinsonism are not well established. There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings.; Objective: We compared the incidence of parkinsonism after new treatment with risperidone, olanzapine, or […]
A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women
Tierney, Mary C.,
Oh, Paul,
Moineddin, Rahim,
Greenblatt, Ellen M.,
Snow, W. Gary,
Fisher, Rory H.,
Iazzetta, John,
Hyslop, Peter St George,
MacLusky, Neil J.
We examined whether estradiol and norethindrone hormone therapy (HT) prevented decline in delayed verbal recall in older women with normal to mildly impaired memory functioning. This was a 2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61-87, randomly assigned to receive 1 mg 17-beta estradiol daily and 0.35 mg norethindrone 3 days/week or daily […]
Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial
Yancheva, S.,
Ihl, R.,
Nikolova, G.,
Panayotov, P.,
Schlaefke, S.,
Hoerr, R.
Objective: This randomised, double-blind exploratory trial was undertaken to compare treatment effects and tolerability of EGb 761(R), donepezil and combined treatment in patients with AD and neuropsychiatric features.; Method: We enrolled 96 outpatients, aged 50 years or above, who met the NINCDS/ADRDA criteria for probable AD, scored below 36 on the TE4D, a screening test […]
Vitamins B(12), B(6), and folic acid for cognition in older men
Ford, A. H.,
Flicker, L.,
Alfonso, H.,
Thomas, J.,
Clarnette, R.,
Martins, R.,
Almeida, O. P.
Objective: To investigate whether supplementing older men with vitamins B(12), B(6), and folic acid improves cognitive function.; Methods: The investigators recruited 299 community-representative hypertensive men 75 years and older to a randomized, double-blind controlled clinical trial of folic acid, vitamin B(6), and B(12) supplementation vs placebo over 2 years. The primary outcome of interest was […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study
Doody, Rachelle S.,
Ferris, Steven,
Salloway, Stephen,
Yijun, Sun,
Goldman, Robert,
Yikang, Xu,
Gao, Jeff,
Murthy, Anita K.
Following a 48-week, double-blind, randomized, placebo-controlled trial of donepezil in 821 patients with amnestic mild cognitive impairment (aMCI), safety and tolerability of donepezil (10 mg) were further evaluated in a 28-week extension study. Of 499 participants who completed the double-blind phase, 145 enrolled in the open-label study. Adverse events (AEs) were recorded throughout. Overall, 57.4% […]
Efficacy of akatinol memantine in moderate cognitive impairments
A six-month open clinical trial of the efficacy of Akatinol was conducted in 40 patients with moderate cognitive impairments (MCI) using piracetam (20 patients) as reference agent; mean age was 67.7 +/- 7.2 years. Patient status was evaluated using a number of scales, questionnaires, and neuropsychological tests prior to treatment and at three and six […]
Day care at green care farms: a novel way to stimulate dietary intake of community-dwelling older people with dementia?
De Bruin, S. R.,
Oosting, S. J.,
Tobi, H.,
Blauw, Y. H.,
Schols, J. M. G. A.,
De Groot, C. P. G. M.
Objective: This study aimed to compare dietary intake of older people with dementia receiving day care at regular day care facilities (RDCFs) or at so-called green care farms (GCFs).; Design and Settings: A comparative cross-sectional study was performed at 10 GCFs and 10 RDCFs in the Netherlands.; Participants: 30 subjects from GCFs and 23 subjects […]